TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma
Shots:
- The approvals is based on P-II UNITY-NHL trial involves assessing Ukoniq (800 mg- qd) in 69 patients with MZL who has received at least 1 prior anti-CD20 based regimen and in 117 patients with FL who received at least 2 prior systemic therapies
- Results: ORR (49% vs 50%) as assessed by IRC- CR (16% vs 3.4%)- PR (33% vs 39%)- DoR of FL was 11.1 mos.
- Ukoniq is the 1st oral inhibitor of PI3K delta and CK1 epsilon. Additionally- it has received BTD for MZL and ODD for MZL and FL
Ref: TG Therapeutics | Image: Seeking Alpha
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com